Serendip Innovations
Plant-produced RNA delivery vectors for pharmaceutical companies developing targeted RNA therapies
Highlights
- Young companyFounded 2023
- New on EvolcAdded 2026-11-10
About Serendip Innovations
Serendip Innovations develops a platform that co-produces RNA with programmable, non-viral plant-derived virus-like particles (phytoVLPs) for targeted delivery beyond the liver. The company presents in vivo cell therapies, including CAR-T and CAR-NK approaches, as an initial application.
It works with pharmaceutical companies through co-development and licensing partnerships. The company is based in Illkirch-Graffenstaden, France, and was founded in 2023.
Product: A plant-based platform for co-producing RNA with programmable non-viral vectors for targeted delivery.
Jobs at Serendip Innovations
More biotech & pharma companies
Sfri
Manufacturer of in vitro diagnostic instruments and reagents for laboratories and medical professionals worldwideNew on EvolcSmartlife Biosciences
Sequencing, oligonucleotide synthesis and bioinformatics services for research laboratories and scientistsYoung companyNew on EvolcSparingvision
Develops gene-agnostic gene therapies for patients with inherited retinal diseases and other blinding conditionsNew on EvolcSpartha Medical
Biopolymer coatings and testing services that help healthcare and cross-sector companies prevent microbial contaminationNew on EvolcSpore.Bio
AI-based, culture-free microbial detection device and consumables for quality control in factories, from pharma and beveragesYoung companyRemote-friendlySqy Therapeutics
Develops antisense oligonucleotide drug candidates for people with genetic diseases, particularly Duchenne muscular dystrophyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
